SCHEMBL1897756

SCHEMBL1897756

CC/C(=C\C(=O)O)c1c(Oc2ccc(NC(=O)Nc3ccc(F)cc3)cc2)ccnc1N

nearest known ligand 0.49

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.49
PDGFRA P16234 10/20 0.49
FLT3 P36888 1/20 0.44
RET P07949 1/20 0.44
MET P08581 4/20 0.42
BRAF P15056 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
CDK8 P49336 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1892230 0.84 KDR (0.45) KDRPDGFRARETMETBRAF
SCHEMBL1893901 0.83 BTK (0.35) KDRPDGFRA
SCHEMBL1897761 0.79 KDR (0.49) KDRPDGFRAFLT3RETMET
SCHEMBL1897541 0.78 PDGFRA (0.41) KDRPDGFRA
SCHEMBL3504543 0.77 KDR (0.51) KDRPDGFRAFLT3RETMET
SCHEMBL3504542 0.77 KDR (0.51) KDRPDGFRAFLT3RETMET
SCHEMBL12500115 0.76 KDR (0.54) KDRPDGFRAFLT3RETMET
SCHEMBL1897753 0.74 KDR (0.48) KDRPDGFRARETMETBRAF
SCHEMBL1897758 0.74 KDR (0.48) KDRPDGFRARETMETBRAF
SCHEMBL12673776 0.74 KDR (0.48) KDRPDGFRARETMETBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973160-B2 Nitrogen-containing aromatic derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-07-05 US disclosed
US-20110118470-A1 NITROGEN-CONTAINING AROMATIC DERIVATIVES FUNAHASHI YASUHIRO 2011-05-19 US disclosed
US-7253286-B2 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI CO., LTD (JP) 2007-08-07 US disclosed
US-20040053908-A1 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053908-A1 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective VEGFA, UACA, UTS2R KDR 22/4885PDGFRA 1572/4885FLT3 980/4885
US-20110118470-A1 NITROGEN-CONTAINING AROMATIC DERIVATIVES GNG2, GCG, FRG1 KDR 2782/4885PDGFRA 3135/4885FLT3 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.